Stanford researchers discovered compound 368, which enhances naloxone's effects in reversing opioid overdoses.

Compound 368 combines naloxone with a negative allosteric modulator (NAM) of the opioid receptor.

In mice, this combination increases naloxone's potency and duration without worsening withdrawal symptoms.

The new approach offers hope against potent synthetic opioids like fentanyl and morphine at lower doses.

While not ready for human trials, the research team aims to refine the compound for longer-lasting effects.

Research published in Nature highlights the compound's potential to increase naloxone's effectiveness.

Advancements in understanding GPCRs and opioid receptors, along with DNA-encoded libraries, offer hope for safer, more effective pain management and addiction treatments.